Differences

This shows you the differences between two versions of the page.

--- covid-19:treatments:sotrovimab [2022/01/14 22:23]
brian
+++ covid-19:treatments:sotrovimab [2023/03/18 23:36] (current)
liam
@@ Line 8: / Line 8: @@
 Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody therapeutic was granted on May 26, 2021
+==Clinical Trials==
+COMET-ICE Phase 3 RCT: 1,057 adult participants were randomized to sotrovimab or placebo. The trial demonstrated a 79% reduction in hospitalization (6/528 vs placebo 30/529) for those that received the treatment.(([[https://www.medrxiv.org/content/10.1101/2021.11.03.21265533v1|Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial]]))
 ==Sales==
-U.S.A. purchased 1.7 million doses
+January 2022 U.S.A. purchased 600,000 doses((https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-united-states-government-0)) \\
+November 2021 U.S.A. purchases $1 billion worth of the mab((https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-united-states-government))
+===== External links =====
+  * [[https://en.wikipedia.org/wiki/Sotrovimab|Wikipedia]]